Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global market for Dry Eye Syndrome treatments is anticipated to expand from USD 6.59 billion in 2025 to USD 9.76 billion by 2031, reflecting a compound annual growth rate of 6.76%. Therapeutic options for this multifactorial condition include various pharmaceuticals, medical devices, and surgical methods aimed at easing symptoms, stabilizing the tear film, and restoring balance to the ocular surface. This market growth is primarily fueled by the rising worldwide incidence of dry eye, which is closely tied to aging demographics and growing digital screen usage. Additionally, increased recognition of the importance of early detection and treatment among medical professionals and the general public is propelling the industry forward. Notably, the European Society of Ophthalmology estimated that approximately 11.5% of European adults experienced dry eye disease in 2025, highlighting a vast demographic in need of effective treatments.

A major hurdle limiting market growth is the ongoing difficulty in creating therapies that deliver lasting remission or effectively target the varied underlying causes across all subtypes of the disease. This limitation often results in patient frustration, as current approaches typically emphasize managing symptoms rather than providing definitive cures.

Market Driver

The rising worldwide incidence of dry eye syndrome, driven by changing lifestyles and demographics, serves as a major engine for market expansion. An expanding elderly population, which is especially prone to ocular surface disorders, continues to widen the demographic needing medical care. Additionally, the extensive use of digital screens for both professional and personal activities leads to less frequent blinking and greater eye strain, worsening symptoms even in younger individuals. Research shared at the 43rd Congress of the European Society of Cataract and Refractive Surgeons in October 2025 revealed that 58% of people in the US and Europe experienced dry eye symptoms. This high prevalence highlights the urgent demand for reliable treatments, stimulating both new diagnoses and continuous care requirements.

Another significant growth driver is the continuous progress in treatment methodologies, which helps fulfill unmet clinical needs and boosts patient results. New classes of medications and advanced delivery mechanisms improve both the effectiveness and tolerability of treatments, thereby encouraging better patient compliance and broadening the market. Highlighting this trend, an Alcon press release from May 2025 announced FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, a pioneering TRPM8 receptor agonist for dry eye disease. These innovations equip eye care specialists with highly focused, efficient resources that drive up prescription volumes. The commercial impact of these novel therapies is evident, as shown in Tarsus Pharmaceuticals' February 2026 Form 10-K, which reported $451.4 million in net sales for XDEMVY throughout 2025.

Market Challenge

The worldwide market for Dry Eye Syndrome treatments encounters a major obstacle regarding the inability of current therapies to ensure prolonged remission or fully resolve the distinct root causes across different disease variations. Available interventions primarily prioritize alleviating symptoms instead of providing a true cure, which often leaves patients feeling dissatisfied. The industry's dependence on temporary symptom management, rather than permanent improvement, hinders broader market expansion by trapping patients in ongoing, yet frequently inadequate, treatment loops.

As a result of these shortcomings, many patients view existing treatments as inadequate or poorly customized to their unique circumstances. Demonstrating this issue, data from the European Society of Cataract and Refractive Surgeons in 2025 indicated that a mere 25% of individuals believed their dry eye regimen was suitably personalized. Such dissatisfaction leads to lower treatment compliance, less willingness to try novel therapies, and a reluctance to spend money on options that fail to guarantee permanent relief. Ultimately, overall market growth is restricted because patients struggle to find interventions that genuinely alter the disease course or offer total healing.

Market Trends

A major trend shaping the global dry eye treatment landscape is the ongoing advancement of device-centric therapies. Moving past conventional eye drops, these modern innovations provide precise and long-lasting relief, especially for individuals suffering from meibomian gland dysfunction (MGD), the primary culprit behind evaporative dry eye. Utilizing technologies like thermal pulsation and intense pulsed light (IPL), these devices target the root causes to enhance gland performance and stabilize the tear film. Illustrating this momentum, Johnson & Johnson reported in January 2026 that its MedTech vision division saw an 8.9% increase in its fourth-quarter 2025 financial results, achieving $1.4 billion and highlighting the success of device-inclusive ophthalmic solutions. This evolution points to a growing embrace of holistic care models where eye care professionals combine advanced diagnostic and therapeutic devices in their daily practice.

Additionally, the market is heavily influenced by a rising consumer shift toward preservative-free medications, spurred by a better understanding of how preservatives can harm the surface of the eye. Individuals managing chronic dry eye often depend on long-term care and actively seek substitutes for conventional drops that use ingredients like benzalkonium chloride (BAK), which can worsen irritation and damage ocular tissues. Offering preservative-free solutions in both single-use vials and multi-dose containers has significantly improved user comfort and compliance. Highlighting this shift, Bausch + Lomb's February 2026 earnings call noted that its consumer dry eye division, featuring preservative-free items, achieved $116 million in fourth-quarter 2025 revenue. This robust financial outcome emphasizes the escalating need for safer, milder treatments, prompting companies to broaden their preservative-free portfolios in both prescription and over-the-counter markets.

Key Market Players

• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Sun Pharmaceuticals Industries Limited
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Oyster Point Pharma, Inc.
• Alcon Inc.
• GlaxoSmithKline plc

Report Scope

In this report, the Global Dry Eye Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

• Evaporative Dry Eye Syndrome
• Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

• Cyclosporine
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Dry Eye Syndrome Treatment Market, By Type:

• Prescription
• Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dry Eye Syndrome Treatment Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.